Vaccine plus immunotherapy for KRAS-mutant cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have either advanced (stage IV) colorectal cancer that is MMR-p or advanced pancreatic cancer.
- Your tumor must have a specific KRAS gene mutation that the vaccine targets.
- You need to be in fairly good health, able to take care of yourself (ECOG 0), and have a life expectancy of at least 3 months.
- You cannot have had immunotherapy before, and you must not have active autoimmune disease or other serious health issues like untreated infections or lung problems.
- You must be willing to have two tumor biopsies (small tissue samples taken with a needle) if safe to do so.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.